Baculovirus expression system is a technique that uses Baculovirus as a vector to introduce foreign genes into insect cells, mainly for recombinant protein expression. This system is recognized as an important platform for the production of therapeutic proteins, vaccines and other commercially valuable proteins.
Market key trends:
One of the key trends in the Baculovirus expression system market is the growing demand for insect cell-based expression systems over prokaryotic and mammalian expression systems. Baculovirus expression system allows the production of properly folded, functionally active and mammalian-like recombinant proteins, which is a major advantage over bacterial and yeast expression systems. It also addresses some of the limitations of mammalian cell-based expression in terms of scalability, safety and cost. This is increasing the preference of researchers and companies for baculovirus expression system.
The global Baculovirus Expression System Market Share is estimated to be valued at US$ 368.5 Mn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Strength: The Baculovirus expression system provides eukaryotic post translational modifications like phosphorylation, acetylation, glycosylation etc. which are important for the functional and structural properties of complex proteins. This makes it an ideal platform for producing therapeutic proteins.
Weakness: The production process is complex involving multiple steps of cloning, transfection, infection, expression and purification which increases the production cost. Scale up from research to industrial level requires optimization at each step.
Opportunity: Growing biopharmaceutical industry, increasing demand for biologics and therapeutic proteins has opened up opportunities for commercialization of baculovirus expression platform. Many companies are focusing on developing high yielding cell lines and automated optimized processes to reduce production costs.
Threats: Presence of established microbial and mammalian expression systems acts as competition. Stringent regulatory requirements for developing viral vectors for human therapeutic use poses challenges.
The global Baculovirus Expression System market is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing demand for recombinant proteins and therapeutic biologics.
North America is expected to dominate the global Baculovirus Expression System market during the forecast period owing to presence of major biopharma companies, growing biologics industry and availability of advanced research infrastructure in the region. Asia Pacific region is anticipated to exhibit fastest growth driven by increasing government funding for life science research, low production costs and growing outsourcing activities by multinational companies to the region.
Key players operating in the Baculovirus Expression System are Thermo Fisher Scientific, Merck KGaA, Takara Bio, Agilent Technologies, Oxford Expression Technologies, Promega Corporation, Qiagen N.V., Bio-Rad Laboratories, New England Biolabs, Genscript Biotech Corporation, Syngene International Limited, Sartorius AG, Aragen Bioscience, Vivopure, Creative Biogene, Absolute Antibody, Rockland Immunochemicals, Protein Technologies Inc., Proteogenix, Virovek.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it